journal article·2026-07

Disrupting the Oxidative Stress–Inflammation–Corneal Neovascularization Cycle with Ultrasmall Nanoparticles

Yue Wu, Nan Zhao, Xue Liu, Zhongxing Chen, Xiaomin Huang, Hongxian Pan, Mengmei Zhu, Zheyu Li, Xinyu Jiang, Xueyu Fu, Haochen Liu, Weiping Wang, Xin Chen, Manli Deng, Jihong Wu, Yi Shao, Wei Tao, Mei Yang, Xingtao Zhou, Jinhai Huang

Advanced Materials· Volume 38· Issue 42
Publisher page

Abstract

ABSTRACT Corneal neovascularization (CoNV) is a primary contributor to corneal scarring and vision impairment. During its initiation and progression, inflammatory reactions and oxidative stress synergistically trigger a pathological vicious cycle of oxidative stress, inflammation, and angiogenesis, posing a severe therapeutic challenge. In this study, a noninvasive transepithelial therapeutic strategy using ultrasmall polydopamine nanoparticles (UPDA NPs) with triple effects is developed. Their unique small size, approximately 3 nm, greatly enhances their radical‐scavenging capability and facilitates superior transepithelial delivery. Extensive research demonstrated that the obtained UPDA NPs possess excellent anti‐inflammatory, antioxidant, and anti‐angiogenic properties. By scavenging reactive oxygen species (ROS), activating the nuclear factor erythroid 2–related factor 2 (NRF2) antioxidant pathway, and suppressing multiple proangiogenic signaling cascades, they can disrupt the pathological cycle of inflammation, oxidative stress, and neovascularization at molecular, cellular, and animal levels. In an alkali‐burned mouse model, UPDA NPs notably reduce CoNV area and length, accelerate corneal repair, and exhibit no local or systemic toxicity, providing a new nanomedicine with translational potential for precise treatment of CoNV.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Corneal Surgery and Treatments · Corneal surgery and disorders · Wound Healing and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Eye Institute and Department of Ophthalmology, NHC Key Laboratory of Myopia and Related Eye Diseases, Eye & ENT Hospital Fudan University Shanghai China

Key Laboratory of Myopia and Related Eye Diseases Chinese Academy of Medical Sciences Shanghai China

Shanghai Research Center of Ophthalmology and Optometry Shanghai China

School of Health Sciences and Engineering University of Shanghai for Science and Technology Shanghai China

School of Ophthalmology and Optometry and Eye Hospital Wenzhou Medical University Wenzhou Zhejiang China

State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong; Department of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak‐Sum Research Centre The University of Hong Kong Hong Kong China

Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine National Clinical Research Center for Eye Diseases Shanghai China

Center For Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

Funding

National Natural Science Foundation of China · Science and Technology Commission of Shanghai Municipality

References (43)

Show source-provided references
1. 10.1016/j.exer.2020.10836310.1016/j.exer.2020.108363 ↗
2. 10.1016/S0039-6257(98)00035-610.1016/S0039-6257(98)00035-6 ↗
3. 10.1159/00004828910.1159/000048289 ↗
4. 10.1136/bmj.309.6946.4310.1136/bmj.309.6946.43 ↗
5. Treatment Regimens for Administration of Anti‐vascular Endothelial Growth Factor Agents for Neovascular Age‐related Macular Degeneration
6. 10.1016/j.ophtha.2008.02.01310.1016/j.ophtha.2008.02.013 ↗
7. 10.2147/OTT.S20545710.2147/OTT.S205457 ↗
8. 10.1016/j.ijbiomac.2020.06.14810.1016/j.ijbiomac.2020.06.148 ↗
9. 10.1007/s00204‐023‐03476‐610.1007/s00204‐023‐03476‐6 ↗
10. 10.3390/ijms22191070110.3390/ijms221910701 ↗
11. 10.1016/j.cej.2023.14714710.1016/j.cej.2023.147147 ↗
12. 10.1021/acsnano.4c0042310.1021/acsnano.4c00423 ↗
13. 10.1002/btm2.1049910.1002/btm2.10499 ↗
14. 10.1002/adma.20250872610.1002/adma.202508726 ↗
15. 10.1186/s40824‐019‐0175‐910.1186/s40824‐019‐0175‐9 ↗
16. 10.1021/acsnano.9b0443610.1021/acsnano.9b04436 ↗
17. 10.1126/sciadv.adf409810.1126/sciadv.adf4098 ↗
18. 10.1016/j.jconrel.2014.06.04310.1016/j.jconrel.2014.06.043 ↗
19. 10.1039/D0BM01070G10.1039/D0BM01070G ↗
20. 10.1093/nar/gkae97310.1093/nar/gkae973 ↗
21. 10.3390/nano1310165410.3390/nano13101654 ↗
22. 10.1016/j.bioactmat.2025.07.00110.1016/j.bioactmat.2025.07.001 ↗
23. 10.3390/ijerph1811588710.3390/ijerph18115887 ↗
24. 10.1016/j.mtbio.2023.10054410.1016/j.mtbio.2023.100544 ↗
25. 10.3390/ph1612164210.3390/ph16121642 ↗
26. 10.3390/pharmaceutics1405095910.3390/pharmaceutics14050959 ↗
27. 10.1016/j.bioactmat.2025.07.03010.1016/j.bioactmat.2025.07.030 ↗
28. 10.1039/D1CS00044F10.1039/D1CS00044F ↗
29. 10.1016/j.biomaterials.2018.12.01510.1016/j.biomaterials.2018.12.015 ↗
30. 10.3390/ijms2313727810.3390/ijms23137278 ↗
31. 10.1111/cas.1348210.1111/cas.13482 ↗
32. 10.1186/s12951‐025‐03594‐610.1186/s12951‐025‐03594‐6 ↗
33. 10.1038/cddis.2012.20310.1038/cddis.2012.203 ↗
34. 10.3390/antiox1209172810.3390/antiox12091728 ↗
35. 10.1016/j.aninu.2022.06.01410.1016/j.aninu.2022.06.014 ↗
36. 10.1016/j.mtbio.2024.10107110.1016/j.mtbio.2024.101071 ↗
37. 10.1002/btm2.1027610.1002/btm2.10276 ↗
38. 10.1021/acsabm.3c0045810.1021/acsabm.3c00458 ↗
39. 10.1021/acs.molpharmaceut.7b0102810.1021/acs.molpharmaceut.7b01028 ↗
40. 10.1016/j.ophtha.2006.01.03410.1016/j.ophtha.2006.01.034 ↗
41. 10.1001/archopht.1978.0391006041900310.1001/archopht.1978.03910060419003 ↗
42. 10.1002/eji.183011101310.1002/eji.1830111013 ↗
43. 10.1016/S1350‐9462(00)00013‐610.1016/S1350‐9462(00)00013‐6 ↗